"They’re priced for profits, not patients.” That’s the critique from Hims & Hers Health’s buzzy — and controversial — Super ...

When Trova Wine and Market shut its doors last month after nearly five years in business in Dallas, owner Michelle Bonds pointed to an unexpected reason for closure: GLP-1 weight loss drugs like ...

A majority with overweight/obesity discontinue within a year, but the rate is higher among those without type 2 diabetes.

A well-known class of drugs used to manage type 2 diabetes and control weight could offer hope for patients who also struggle ...

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

Objective—Glucagon-like peptide 1 (GLP-1) exerts beneficial antidiabetic actions via effects on pancreatic β- and α-cells. Previous studies have focused on the improvements in β-cell function ...

Compounded weight-loss medications, such as those promoted in the Hims & Hers commercial, aren’t approved by the Food and ...

About The Study: This cross-sectional study showed websites that sell compounded glucagon-like peptide-1 receptor agonists ... Compounded medications contain the same active ingredients as ...

The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy, but risk is elevated in the first year of treatment, according to a ...

Glucagon-like peptide-1 receptor (GLP-1) agonists — which contain either semaglutide or ... but previous studies have linked the drugs to other, unexpected benefits. Researchers at Washington ...